Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis' ADXS-HPV Granted Orphan Drug Designation for Treatment of HPV-Associated Anal Cancer

Business Wire August 14, 2013

Advaxis Updates Business Outlook for 2013

Business Wire July 25, 2013

Advaxis Announces ADXS-cHER2 Demonstrates Significant Survival Advantage in Ongoing Canine Osteosarcoma Study

Business Wire July 17, 2013

Update on Advaxis Announces 1-for-125 Reverse Stock Split and Decrease in Authorized Shares of Common Stock

Business Wire July 16, 2013

Advaxis Announces Appointment of New Member to Its Board of Directors

Business Wire July 16, 2013

Advaxis Announces 1-for-125 Reverse Stock Split and Decrease in Authorized Shares of Common Stock

Business Wire July 15, 2013

Advaxis Requests Orphan Drug Designation for Treatment of HPV-Associated Anal Cancer with ADXS-HPV

Business Wire June 24, 2013

Advaxis Announces Voting Results of 2013 Annual Meeting of Stockholders

Business Wire June 17, 2013

Advaxis Requests Orphan Drug Designation for Treatment of HPV-Associated Head and Neck Cancer with ADXS-HPV

Business Wire June 11, 2013

Advaxis Issues Letter Advising Stockholders to Vote FOR Proposals 2 and 3 of Proxy Statement

Business Wire June 10, 2013

Advaxis Requests Orphan Drug Designation for Treatment of Cervical Cancer with ADXS-HPV

Business Wire June 7, 2013

Advaxis Announces Withdrawal of Proxy Statement Proposal to Amend Its Incentive Plan at This Time

Business Wire June 6, 2013

Advaxis Announces Amendment of Proxy Statement Supplement Further Reduction in Share Capital Proposal

Business Wire June 4, 2013

Advaxis Reports Survival and New Analysis for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 American Society of Clinical Oncology Annual Meeting

Business Wire June 2, 2013

Advaxis Announces Filing of Proxy Statement Supplement and New Annual Meeting Date

Business Wire May 23, 2013

Advaxis Announces Promotion of Dr. Robert Petit and Daniel J. O'Connor

Business Wire May 6, 2013

Advaxis Announces 2013 Annual Meeting of Stockholders

Business Wire May 6, 2013

Advaxis Reports Encouraging Preliminary Data from Penn Phase 1 ADXS-cHER2 Canine Osteosarcoma Study

Business Wire April 29, 2013

Advaxis Announces First Patient Dosed in Brown University Sponsored Anal Cancer Study

Business Wire April 22, 2013

Advaxis and FusionVax Sign a Memorandum of Understanding for the License of Advaxis' ADXS-HPV in Asia

Business Wire April 22, 2013